Increasing plasma calprotectin (S100A8/A9) is associated with 12-month mortality and unfavourable functional outcome in critically ill COVID-19 patients

Table 4 Associations between plasma calprotectin levels and the use of mechanical ventilation or renal replacement therapy

	Model	IMV			CRRT
		OR^ab	CI	p	OR^ab	CI	p
Calprotectin day 0	1	1.72	1.39–2.12	< 0.001	1.02	0.80–1.32	0.86
Calprotectin day 0	2	1.73	1.39–2.16	< 0.001	0.99	0.76–1.29	0.92
Calprotectin day 7	1	1.93	1.47–2.53	< 0.001	1.51	1.10–2.07	0.012
Calprotectin day 7	2	1.22	0.78–1.90	0.39	1.58	1.04–2.42	0.034
Increasing calprotectin day 0–day 7	1	2.28	1.14–4.56	0.019	2.05	1.08–3.88	0.028
Increasing calprotectin day 0–day 7	2	2.23	1.10–4.53	0.027	2.07	1.07–4.00	0.031

Adjustment models: Model 1: unadjusted. Model 2: adjusted for age, sex, BMI, hypertension, smoking and creatinine
GOSE Glasgow Outcome Scale Extended
^aOdds ratio (OR) expressed per 1 Standard deviation (SD) increase in calprotectin
^bOR for outcomes in patients with increasing calprotectin levels from day 0 to day 7

ISSN: 2052-0492